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Therapy responseAbstract Background/aim: Hepatitis C virus (HCV) infection usually progress to chronic infection
with subsequent cirrhosis and cancer. Therapies aim to eradicate the virus andprevent further progres-
sion. Interferon is claimed to have anti-ﬁbrotic effect.Histopathology is the gold standard in diagnosis
and grading of hepatic ﬁbrosis, but transient elastogram (Fibroscan) can be used as alternative non-
invasive modality. This prospective study aimed to evaluate the accuracy of ﬁbroscan in diagnosis of
liver ﬁbrosis, and assess the effect of antiviral therapy on ﬁbrosis stages in HCV patients.
Patients and methods: The study was conducted from September 2012 toDecember 2014 as a project
funded by Science and Technology Development Fund, Egypt, Grant No. 3448. It included 498
patients; 150 HCV cirrhotic patients as control, and 348 HCV naive patients grouped according to
their liver biopsy into; mild (group I) and moderate (group II) ﬁbrosis. They were examined using
ﬁbroscan (Echosens, Paris, France, device 502,Mprobe) before, 12, 24, and 48 weeks of therapy, with
300 patients (150 patients in each group) completed follow-up regardless of their response. The results
of ﬁbroscan were compared to each other and to liver biopsy.
Results: Fibroscan can diagnose F1 at 6 kPa with 26% sensitivity, 8% speciﬁcity, AUC= 0.037; F2 at
level of 7 kPa with 84.6% sensitivity, 71.3% speciﬁcity, AUC= 0.692 and F3 at 9.5 kPa with 96% sen-
sitivity, 97% speciﬁcity, AUC= 0.997. The ﬁbrosis results had regressed signiﬁcantly after 48 weeks of
starting therapyof bothpatients’ groups (p< 0.05).When categorizedby response to therapy, responders
showed signiﬁcant decline in their ﬁbroscan scores compared to non-responders of same ﬁbrosis degree.
Conclusion: Fibroscan correlated with histopathology in moderate (F2–F3), but not mild (F1) ﬁbrosis.
The degree of ﬁbrosis regresses signiﬁcantly in HCV responders on anti-viral INF based therapy. Besides
its accuracy as noninvasive device in detecting degree of ﬁbrosis, ﬁbroscan can be very useful in assessment
of degree of ﬁbrosis during and after therapy.
 2016 The Egyptian Society of Radiology andNuclearMedicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Infection with hepatitis C virus (HCV) is a common problem
worldwide. Most cases progress to chronic infection with its
complications. As a consequence of progressive HCV liver
ﬁbrosis, cirrhosis, liver failure, and hepatocellular carcinoma
may occur (1). Histological assessment of liver injury and
ﬁbrosis is the gold standard test. It is important for making
treatment decisions, as well as for predicting prognosis and
therapeutic outcome in chronic liver disease including HCV.
However, liver biopsy is an invasive procedure, limited by cost,
morbidity, and sampling errors. Moreover, it provides a static
measure of ﬁbrosis as its repetition is tedious (2,3).
As accurate noninvasive methods of monitoring changes in
ﬁbrosis would be helpful in following the natural history of the
disease and monitoring potential anti-ﬁbrotic responses to
antiviral or other treatment modalities, several noninvasive
predictive indices for hepatic ﬁbrosis based on direct and indi-
rect serum markers, or imaging modalities to measure liver
stiffness, such as transient elastography (ﬁbroscan) have been
developed. Transient elastography (Fibroscan; Echosens,
Paris, France) is a novel method for measuring liver stiffness
as a surrogate of ﬁbrosis. It has been validated in patients with
various disorders including chronic viral hepatitis and has
gained widespread use due to its simplicity, rapid results, and
ease of incorporation into an outpatient setting (4,5).
The objective of this prospective study was to evaluate the
accuracy of ﬁbroscan in diagnosing liver ﬁbrosis compared to
liver biopsy in HCV patients, and to assess the effect of antivi-
ral therapy on different stages of ﬁbrosis.2. Patients and methods
This study was performed on 498 patients, in the period from
September 2012 to December 2014 as a project funded by
Science and Technology Development Fund, Egypt, Grant
No. 3448. Of them three hundred and forty eight (348) patients
seek anti-HCV treatment through health insurance clinics or
national anti-HCV program and accepted to take part in this
study and signed the informed consent.
Patients were classiﬁed according to their liver biopsy
results into group I: 163 patients with mild ﬁbrosis (F0–F1),
group II: 185 patients with moderate ﬁbrosis (F2–3), and
group III: 150 patients not ﬁt for therapy as control (f4 or
cirrhosis).
All treated patients (groups I and II) were homogenously
collected according to Egyptian national protocol for treat-
ment of HCV. All laboratory assessments of treated patients
were performed centrally through the national or health insur-
ance laboratories, with liver biopsy size of 15 mm at least, and
all biopsies were evaluated by a single experienced liver
histopathologist. The genotyping for HCV was not performed
on the patients in our study, since approximately 90% of infec-
tions in Egypt are due to genotype 4 (6) and the Egyptian
National Committee for Control of Viral Hepatitis does not
recommend routine genotyping.
They all met the following inclusion criteria: age (18–60)
years, positive anti-HCV antibodies, HCV-RNA level greater
than 1000 IU/mL, body mass index (BMI) <30 calculated
as (weight in kilograms/squared height in meters), normala-fetoprotein, serum bilirubin <1 mg%, a liver biopsy speci-
men taken within one month prior to study entry, neutrophil
and platelet counts of at least 2000 lL and 100,000 lL respec-
tively, hemoglobin values of at least 12 g/dL for women and
13 g/dL for men, and creatinine levels less than 1.2 mg/dL.
These were the same data needed for inclusion in standard
of care therapy at this time (peg interferon + ribavirin).
Patients were excluded from this study if they had hepatitis
B virus infection, human immunodeﬁciency virus infection,
autoimmune disorders, clinically signiﬁcant cardiac or cardio-
vascular abnormalities, evidence of malignant neoplastic dis-
eases or concomitant immunosuppressive medication.
Liver biopsy specimens were obtained under complete asep-
tic procedures to retrieve 15 mm core. The specimen was pro-
cessed and stained with hematoxline and eosine. Fibrosis was
staged on a 0–4 scale: F0, no ﬁbrosis; F1, portal ﬁbrosis with-
out septa; F2, portal ﬁbrosis and few septa; F3, numerous
septa without cirrhosis; and F4, cirrhosis according to META-
VIR scoring system (Bedossa P1996).
The patients on antiviral therapy were followed by PCR at
weeks 12, 24, and 48 of therapy. Fibroscan examination (using
ﬁbroscan; Echosens, Paris, France, device 502, M probe) was
parallel repeated in the same periods.
2.1. Fibroscan examination
After clinical and ultrasound examination, patient underwent
ﬁbroscan examination. Measurements were taken in the right
lobe of the liver, through the intercostal spaces with the patient
lying in the dorsal decubitus, and the right arm in maximum
abduction. The tip of the probe transducer is covered with cou-
pling gel and placed on the skin between the rib bones at the
level of the right lobe. The operator, assisted by ultrasound
time motion images, locates a portion of the liver that is at
least 6 cm thick and free of large vascular structures. Once
the area to be measured has been located, the operator presses
the probe button to begin acquisition. Acquisitions that do not
have the correct vibration shape or do not correctly follow the
vibration propagation are automatically rejected by the soft-
ware. The success rate is calculated as the number of successful
acquisitions. Ten validated measurements were made on each
patient. The results were expressed in kilopascals (kPa). Only
examination with 10 validated measurements and a success
rate of at least 70% (ratio of the number of successful acquisi-
tions over the total number of acquisitions) were considered
reliable. Shear wave propagation velocity depends on the
severity of hepatic ﬁbrosis. The elastic modulus E expressed
as E= 3qV2, where V is the shear velocity and q is the mass
density (constant for tissues); the stiffer the tissue, the faster
the shear wave propagates. The median value of ten E results
is automatically calculated by software. It was considered
representative of the liver elastic modulus as previously
described (7).
2.2. Statistical analysis
The collected data were analyzed using SPSS software statisti-
cal computer package version 16 (IBM Corp, Armonk, NY,
USA). Data were summarized using mean, standard deviation
(SD), and median for quantitative skewed variables. Kruskal–
Wallis One Way Analysis of Variance on Ranks was used to
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if it was signiﬁcant post hoc Tukey test was used for all pair
wise comparison. Chi square was used to compare response
rate among treated groups. Correlation between ﬁbroscan
results and liver ﬁbrosis stage was done using spearman rank
correlation test. Area under Receiver operator characteristic
(ROC) curves was used to detect cutoff value to each hepatic
ﬁbrosis stage and detect its sensitivity and speciﬁcity for each
stage. The results were considered statistically signiﬁcant when
p< 0.05 for all used tests.
3. Results
The study composed of 3 groups. Group I: started with 163
patients. Of them, 159, 154, and 150 stick to their follow-upTable 1 Demographic data of all studied groups.
Group 1
n= 150
Group 2
n= 150
Group 3
n= 150
Age in years
 Mean ± SD 43.6 ± 8.9 46.6 ± 8 49.2 ± 7.5
 Median 44 47 49
 Range 19–60 19–60 27–64
Sex
 Female 55 44 33
 Male 95 106 117
METAVIR score
 F0 4 0 0
 F1 146 0 0
 F2 0 63 0
 F3 0 87 0
 F4 0 0 150
Table 2 Correlation between liver biopsy and ﬁbroscan
results in studied groups.
Group r p
Group I 0.122 0.12
Group II 0.646* <0.0001
* Signiﬁcant.
Table 3 Comparing ﬁbroscan results before, during and after thera
Group parameter Before 12 w 2
Group I (n = 150)
 Mean ± SD 5.713 ± 1.125 5.677 ± 1.171 5
 Range 2.700–8.700 2.700–8.700 2
 Median 5.900 5.800 5
Responders of group I (n = 81)
 Mean ± SD 6.193 ± 0.950 5.654 ± 1.128 5
 Median 6.2 6.2 5
 Range 3.200–8.700 2.800–8.400 2
Non-responders of Group I (n = 69)
 Mean ± SD 5.123 ± 1.055 5.710 ± 1.234 5
 Median 5.100 5.800 5
 Range 2.80–8.40 2.70–8.60 3
* Signiﬁcant.at 12, 24, and 48 weeks respectively. Group II started with
185 patients. Of them, 169, 162, and 150 stick to their
follow-up at 12, 24, and 48 weeks respectively. So, the data
of 150 patients who completed their follow-up in each group
were only included for analysis. Group III had 150 patients
with cirrhosis without follow-up. Group I with mild ﬁbrosis
had mean age of 43.6 ± 8.9, group II with moderate ﬁbrosis
had mean age of 46.6 ± 8 and group III with advanced ﬁbrosis
and cirrhosis had mean age of 49.2 ± 7.5. There was no signif-
icant difference in age among all studied groups (F= 2.81 &
p= 0.061) (Table 1).
Results of ﬁbroscan and biopsy were available in 348
patients before therapy (163 in group I and 185 in Group II)
and the biopsy correlated positively with ﬁbroscan data in
moderate ﬁbrosis (p< 0.001), but not in mild or no ﬁbrosis
(p= 0.12) (Table 2).
According to standard of care, only groups I and II
received treatment. Among group I, 81/150 (54%) were
responders, while group II had 86/150 (57%) responders.
There was no signiﬁcant difference in response rate between
the two groups (x2 = 0.642). Genotyping for HCV was not
performed in our study (Tables 3 and 4).
Among studied patients only 300 cases completed their
follow-up during and after therapy (groups I and II); their data
were tested using ROC curve with different cutoff values as
follows: For stage F0, we have only 4 cases, so it was not
tested. For F1, at level of 6 kPa to diagnose F1 ﬁbroscan has
sensitivity of 26% and speciﬁcity of only 8%, AUC was
0.037 (95%CI is 0.005–0.068), for F2 at level of 8.8 kPa to
diagnose F2 ﬁbroscan has sensitivity of 2% and speciﬁcity of
50%, but when we used elasticity of 7 kPa ﬁbroscan has sensi-
tivity of 84.6% and speciﬁcity of 71.3% with AUC= 0.692
(95%CI is 0.601–0.784) and for F3 at level of 9.5 kPa to diag-
nose F3 ﬁbroscan has sensitivity of 96% and speciﬁcity of
97%. AUC was 0.997 (95%CI is 0.992–1.003) (Fig. 1).
Among 300 patients who received treatment, response rate
was 54–57%. Changes in transient elastography during ther-
apy were measured in 300 patients who completed their
follow-up (150 patients in each group) at start, 12 weeks,
24 weeks, and 48 weeks of therapy. The clearance of the virus
was associated with decline in liver stiffness measurements.
The Mean ﬁbroscan scores were signiﬁcantly changed in
both groups I and II during and after therapy. When groups
were stratiﬁed according to response the responders of bothpy in group I.
4 w 48 w H p
.584 ± 1.227 5.085 ± 0.819 40.072* <0.001
.700–8.600 3.000–6.800
.000 5
.596 ± 1.245 4.806 ± 0.734 73.117* <0.001
.8 4.8
.700–8.600 3.00–7.00
.574 ± 1.218 5.275 ± 0.816 14.18* 0.003
.800 5.300
.0–7.00 3.0–7.0
Table 4 Comparing ﬁbroscan results before, during and after therapy in group II.
Group parameter Before 12 w 24 w 48 w H p
Group II (n = 150)
 Mean ± SD 11.475 ± 6.252 11.315 ± 5.121 11.036 ± 4.595 9.841 ± 4.142 12.972* 0.005
 Range 2.200–48.000 2.400–42.200 2.200–41.600 3.100–36.000
 Median 10.20 10.20 10.20 9
Responders of group II (n = 86)
 Mean ± SD 12.724 ± 7.585 11.681 ± 5.803 11.191 ± 5.393 8.748 ± 4.339 37.166* <0.001
 Median 10.500 10.300 10.250 8.000
 Range 2.200–48.000 2.400–42.200 2.200–41.600 3.100–36.000
Non responders of Group II (n = 64)
 Mean ± SD 9.797 ± 3.135 10.823 ± 4.019 10.828 ± 3.259 10.259 ± 2.615 4.697 0.195
 Median 9.050 10.200 10.200 10.100
 Range 4.400–22.000 4.30–31.60 4.40–19.30 4.50–18.20
* Signiﬁcant.
Fig. 1 ROC curve for grads of hepatic ﬁbrosis as measured with ﬁbroscan.
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therapy. Non-responders of both groups did not decline their
ﬁbroscan score. On the contrary, it was either signiﬁcantly
increased as in group I or non-signiﬁcantly changed as inTable 5 Comparison of treated patients at different intervals of th
Group Signiﬁcant diﬀerence (p< 0.05)
Before Versus
12 weeks
Before Versus
24 weeks
Before V
48 weeks
Group I (n= 150) No No Yes
Responders of Group I
(n= 81)
Yes Yes No
Non-responders of
Group I (=69)
No Yes Yes
Group II (n= 150) Yes Yes Yes
Responders of Group II
(n= 85)
No No Yes
Non-responders of
Group II
No signiﬁcant diﬀerence in ANOVAgroup II (p= 0.19) (Tables 3–5). Responders start ﬁbroscan
regression in week 12 and persist while non-responders showed
ﬂuctuation in their ﬁbroscan scores during therapy (Figs. 2–5).
A sample of group III was also available (Fig. 6).erapy (Tukey test).
ersus 12 weeks Versus
24 weeks
12 weeks versus
48 weeks
24 weeks versus
48 weeks
No Yes Yes
No Yes No
No Yes No
No Yes Yes
No Yes Yes
Fig. 2 Fibroscan exam in group I responder at start, 12, 24, and 48 weeks (same patient).
Fig. 3 Fibroscan exam in group I non-responder at start, 12, 24, and 48 weeks (same patient).
Fig. 4 Fibroscan exam in group II responder at start, 12, 24, and 48 weeks (same patient).
Fig. 5 Fibroscan exam in group II non-responder at start, 12, 24, and 48 weeks (same patient).
Fig. 6 Samples of ﬁbroscan exam in group III (different patients).
Fibroscan versus liver biopsy 5
6 S. El Saadany et al.4. Discussion
The diagnostic cutoffs for grades of ﬁbrosis calculated in
published studies are very heterogeneous (8). When we com-
pare the results of liver biopsy cutoffs are provided by man-
ufacture for correlating results in HCV patients using ROC
curve and we ﬁnd the following: for F1, at level of 6 kPa to
diagnose F1 ﬁbroscan has low sensitivity and speciﬁcity of
only 8% and AUC was 0.037 (95%CI is 0.005–0.068), and
for F2 at level of 8.8 kPa to diagnose F2 ﬁbroscan has sen-
sitivity of 2% and speciﬁcity of 50% which are very low
parameters.
The data of our patients revealed 7 kPa as a cutoff for F2,
with sensitivity of 84.6% and speciﬁcity of 71.3% with
AUC= 0.692 (95%CI is 0.601–0.784). This cutoff was lower
than that adopted by Ziol et al. (9) (P8.8 kPa for FP 2)
and those speciﬁcally calculated for CHC in the meta-
analysis of Stebbing et al. (10) (P8.5 kPa for FP 2). But it
was in accordance with Castera et al. (11) who reported
7.1 kPa as a cutoff for FP 2.
In a recent study, Boursier et al. (12) studied the diagnostic
accuracy of ﬁbroscan at different cutoffs and stated that accu-
racy for diagnosing signiﬁcant ﬁbrosis (PF2) signiﬁcantly
decreased in patients with median P7.1 kPa. They ﬁnd also
that with IQR/M >0.30 may be considered ‘‘poorly reliable”
in patients with median P7.1 kPa and ‘‘reliable” in patients
with median <7.1 kPa. This is supporting our results which
reﬂect level of 7 kPa as more reliable cutoff in F2 patients.
According to the current deﬁnitions, all the following criteria
have to be met to consider ﬁbroscan result as reliable valid
measurements, success rate >60%, and interquartile range/
median (IQR/M) <0.30 (13–15). None of our patients had
IQR/M >0.30 at any cutoff value in this work. So, we did
not interpret examination results with IQR/M >0.30 as reli-
able result of ﬁbroscan examination.
For patients with METAVARE F3, at level of 9.5 kPa
ﬁbroscan has sensitivity of 96% and speciﬁcity of 97% and
AUC was 0.997 (95%CI is 0.992–1.003). Similar results were
reported by Wong et al. (16) who reported 9 kPa as cutoff
value of F3 in hepatitis B patients with normal ALT. But
higher cutoff was adopted in HCV patients by Ziol et al. (9)
and Castera et al. (11) who reported 12.5 and 14.8 kPa as cut-
off values to diagnose ﬁbrosis of F3 or more. However, they
had 25% and 19.5% cirrhotic patients included in their studies
respectively. So, their results may be overestimated by the
results of F4 and cirrhotic patients included in the same group.
Among 300 patients who received treatment, response rate
was 54–57%. This was much lower than El Khayat et al. (17)
who reported end of therapy response (ETR) after 48 weeks of
peg interferon + ribavirin in genotype 4 to be 80% (38/44
patients), and Shehab et al. (18) who reported 62% ETR in
same genotype but, higher than that reported by Derbala
et al. (19) who reported it to be 43.3%. These variations
may be biased by small sample size used in these studies (44,
50 and 30 patients respectively). Despite genotyping for
HCV was not performed on the patients in our study, yet
approximately 90% of infections in Egypt are due to genotype
4, and previously mentioned studies were performed in Egypt
suggesting no genotypic differences.
Changes in ﬁbroscan during therapy were measured in 300
patients who completed their follow-up at start, 12 weeks,24 weeks, and 48 weeks of therapy. The mean ﬁbroscan scores
were not signiﬁcantly different at baseline between responders
and non-responders. This was different from Patel et al. (20)
who reported that among their 217 patients who perform
ﬁbroscan examination, responders had lower TE results com-
pared to non-responders in same ﬁbrosis degree. However,
Vergniol et al. (21) tested 112 HCV patients receiving antiviral
therapy, and did not ﬁnd any signiﬁcant differences in TE
results at baseline between responders and non-responders,
and similar results were obtained in French study by Hezode
et al. (22), and Japanese’s study by Ziol et al. (9).
It was interesting to observe that, regardless the degree of
ﬁbrosis, responders start ﬁbroscan regression in week 12 and
persist while non-responders showed ﬂuctuation in their TE
scores during therapy. Responders of both groups of ﬁbrosis
had signiﬁcant lower scores throughout the course of therapy,
while non-responders of both groups did not decline their
ﬁbroscan scores. This was in accordance with many previous
studies which reported a decline in serum ﬁbrosis marker
indices or ﬁbroscan measurements in patients with chronic
HCV successfully treated with interferon based therapy
(20,23–25).
In our work, the clearance of the virus was associated with
decline in liver stiffness measurements. This was not clear in
group I who had no or mild ﬁbrosis (stages F0–1) prior to
treatment. Thus, they were incapable of achieving a signiﬁcant
regression in ﬁbrosis. Similar results were obtained by Patel
et al. (20). On the other hand, patients in group II with mod-
erate ﬁbrosis (F2–3) allow for decline of degree of stiffness in
ﬁbroscan to be signiﬁcant.
5. Conclusion
Fibroscan correlated with ﬁbrosis degree in liver biopsy and
can be used as noninvasive tool to diagnose moderate (F2–
F3), but not mild (F1) ﬁbrosis. Elastogram of 7 kPa is more
accurate than 8.8 kPa in diagnosis of moderate ﬁbrosis (F2).
Responders showed signiﬁcant decline in their ﬁbroscan scores
compared to non-responders of same ﬁbrosis degree. Besides
its accuracy as noninvasive device in detecting degree of ﬁbro-
sis, ﬁbroscan can be very useful in assessment of degree of
ﬁbrosis during and after therapy.
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